Astrazeneca

FromAstraZeneca ([email protected])
Subject (124)AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
Preheader (47)͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Typography
Arial
Colors
Text Analysis
Body Words229
Subject Words17
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px716 px
X-Spam Score-1.3
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial